Cagrilintide / Tirzepatide
Blend of cagrilintide (amylin analog) and tirzepatide (GIP/GLP-1 dual agonist), studied for weight management.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
We have not published an audit on Cagrilintide / Tirzepatide. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Combines amylin-receptor agonism (cagrilintide) with GIP/GLP-1 agonism (tirzepatide); studied for appetite regulation and weight management.
Tirzepatide targets two gut-hormone receptors (GLP-1 and GIP) to cut appetite and improve insulin signaling, while cagrilintide adds a third pathway by mimicking the amylin fullness hormone that signals a separate part of the brain you've had enough food.
Reported side effects
The most common side effects are nausea, vomiting, and constipation, which are amplified because both compounds slow gastric emptying, making slow dose escalation critical.
Who should avoid it
People should not add semaglutide, retatrutide, or pramlintide to this stack due to redundant receptor coverage and increased side-effect risk, and anyone considering this combination should note that cagrilintide is investigational and the combination has not been tested in human clinical trials.
What gets monitored
At-home blood test (SiPhox Health At-Home Blood Test) is listed as a recommended supply. No specific lab panels or monitoring parameters are named beyond this. [Source: peptidedosingprotocols.com]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Cagrilintide / Tirzepatide or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Tirzepatide 15.0 mg/week + Cagrilintide 2.4 mg/week (maintenance); sub-maximal example: tirzepatide 10 mg + cagrilintide 1.2 mg | Once weekly24-week ramp + open-ended maintenance; or stabilize tirzepatide at 10-15 mg then add cagrilintide for 12+ weeks; or sub-maximal combination as needed | Subcutaneous | peptidedosingprotocols.comWhat it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
- Once weekly24-week ramp + open-ended maintenance; or stabilize tirzepatide at 10-15 mg then add cagrilintide for 12+ weeks; or sub-maximal combination as needed
- Subcutaneous
- peptidedosingprotocols.com
What it saysHide
(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com]
- Each vial is reconstituted separately using bacteriostatic water (BAC water). Tirzepatide: 5 mg vial + 1.0 mL BAC = 5 mg/mL; 10 mg vial + 2.0 mL BAC = 5 mg/mL; 10 mg vial + 1.0 mL BAC = 10 mg/mL; 30 mg vial + 3.0 mL BAC = 10 mg/mL. Cagrilintide: 5 mg vial + 2.0 mL BAC = 2.5 mg/mL; 10 mg vial + 2.0 mL BAC = 5.0 mg/mL; 10 mg vial + 1.0 mL BAC = 10.0 mg/mL. Cagrilintide is sensitive, inject BAC water down the vial wall and swirl gently; do not shake (amyloid fibril risk); discard cloudy solution. Label every vial with compound name, concentration, and reconstitution date. Both compounds are stable 28-30 days at 2-8 °C once reconstituted. Standard steps: let vial and BAC water reach room temperature (~10-15 minutes); swab both vial stoppers with alcohol. Do not mix the two compounds in one syringe.
Common questions
Can you take cagrilintide and tirzepatide together?
Yes, but not on the same starting day. Standard community protocols run tirzepatide alone for the first 8 weeks (2.5 → 5 mg/week) to confirm GI tolerance, then add cagrilintide at 0.25 mg/week starting Week 9. Both compounds are once weekly. From Week 9 onward, most users dose both on the same day at different injection sites.
How much cagrilintide do you take with tirzepatide?
Most community protocols start cagrilintide at 0.25 mg/week once tirzepatide is established, then step up every 4 weeks to 0.5, 1.0, 1.7, and 2.4 mg/week. Tirzepatide titrates separately from 2.5 mg up to 15 mg/week.
How far apart should I inject cagrilintide and tirzepatide?
Most users inject both on the same day, a few minutes apart at different sites. There is no required time gap. Same day is simpler, but some users split them—tirzepatide Monday and cagrilintide Thursday—to spread out GI side effects during titration. Both compounds have half-lives around 5–8 days, so splitting by a few days does not change overall coverage much.
Can I inject cagrilintide and tirzepatide at the same port (same injection site)?
No. Use different injection sites for each compound—for example, tirzepatide in the abdomen and cagrilintide in the thigh or upper arm. Different sites reduce local irritation, lower the risk of stacked injection-site reactions, and help you tell which compound is causing any reaction. Never mix the two compounds in one syringe.
When does cagrilintide appetite suppression kick in?
Cagrilintide has a long half-life (about 7–8 days), so it takes time to build up. Most users report noticeable appetite suppression by Week 2–3 after starting it. Some report changes within the first week. At the starting 0.25 mg/week dose, effects are usually mild. Stronger satiety effects typically appear after stepping up to 0.5–1.0 mg/week.
Is there any combination data for cagrilintide + tirzepatide?
Yes—one preclinical study. Valdecantos et al. (Diabetes 2024) gave both compounds to obese rats. The combination produced greater weight loss than either compound alone at sub-maximal doses. No human trial has tested the combination as of June 2026. CagriSema (cagrilintide + semaglutide) is the closest human analog with Phase 3 data.
How does this stack compare to CagriSema?
CagriSema pairs cagrilintide with semaglutide (a GLP-1-only drug). It has Phase 3 REDEFINE-1 data showing about 22.7% weight loss at 68 weeks, and an NDA was filed with FDA in December 2025. Cagrilintide + tirzepatide swaps semaglutide for tirzepatide, which adds GIP receptor activity. The cag + tirz combination covers three pathways instead of two, but it has no human trial data of its own.
How do you reconstitute cagrilintide and tirzepatide?
Reconstitute each vial separately with bacteriostatic water. A common setup is tirzepatide 10 mg + 1.0 mL BAC (= 10 mg/mL; a 5 mg dose = 0.50 mL = 50 units on a U-100 syringe) and cagrilintide 5 mg + 2.0 mL BAC (= 2.5 mg/mL; a 1 mg dose = 0.40 mL = 40 units). Inject BAC water slowly down the vial wall and swirl gently—never shake cagrilintide.
Open the reconstitution calculator →Sources
The reference sections above are imported from our compound knowledge base, which classes the evidence for Cagrilintide / Tirzepatide as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
Blend of cagrilintide (amylin analog) and retatrutide (triple GLP-1/GIP/glucagon agonist), studied for weight management.
Investigational fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), studied once weekly for weight management.
Investigational GLP-1 and glucagon receptor dual agonist studied for weight management and metabolic health.
Investigational triple GLP-1 / GIP / glucagon receptor agonist studied for weight management.
Semaglutide is one of the most widely studied weight-loss and diabetes drugs in the world.
Dual GIP and GLP-1 receptor agonist studied for weight management and glycemic control.